Determining an Optimal Oxygen Saturation Target Range Based on Neonatal Maturity: Demonstration of a Decision Tree Analytic

The utility of decision tree machine learning in exploring the interactions among the SpO<sub>2</sub> target range, neonatal maturity, and oxemic-risk is demonstrated. METHODS: This observational study used 3 years of paired age-SpO<sub>2</sub>-PaO<sub>2</sub> dat...

Full description

Bibliographic Details
Main Authors: Thomas E. Bachman, Narayan P. Iyer, Christopher J. L. Newth, Robert LeMoyne
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/13/21/3312
Description
Summary:The utility of decision tree machine learning in exploring the interactions among the SpO<sub>2</sub> target range, neonatal maturity, and oxemic-risk is demonstrated. METHODS: This observational study used 3 years of paired age-SpO<sub>2</sub>-PaO<sub>2</sub> data from a neonatal ICU. The CHAID decision tree method was used to explore the interaction of postmenstrual age (PMA) on the risk of extreme arterial oxygen levels at six different potential SpO<sub>2</sub> target ranges (88–92%, 89–93%, 90–94%, 91–95%, 92–96% and 93–97%). Risk was calculated using a severity-weighted average of arterial oxygen outside the normal range for neonates (50–80 mmHg). RESULTS: In total, 7500 paired data points within the potential target range envelope were analyzed. The two lowest target ranges were associated with the highest risk, and the ranges of 91–95% and 92–96% were associated with the lowest risk. There were shifts in the risk associated with PMA. All the target ranges showed the lowest risk at ≥42 weeks PMA. The lowest risk for preterm infants was within a target range of 92–96% with a PMA of ≤34 weeks. CONCLUSIONS: This study demonstrates the utility of decision tree analytics. These results suggest that SpO<sub>2</sub> target ranges that are different from typical range might reduce morbidity and mortality. Further research, including prospective randomized trials, is warranted.
ISSN:2075-4418